Sanofi withdraws Emerflu application
Sanofi Pasteur has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu.
Sanofi Pasteur has formally withdrawn its application to the European Medicines Agency (EMA) for a centralized marketing authorization for its pandemic influenza vaccine Emerflu.
The vaccine was intended to be used to help prevent influenza during an officially declared pandemic. A core pandemic dossier was submitted in the context of preventing influenza in an officially declared pandemic, according to the mock-up vaccine procedure. According to the EMA, Sanofi Pasteur withdrew the application because the EMA’s Committee for Medicinal Products for Human Use (CHMP) said that the data did not allow the committee to conclude a positive benefit/risk balance.
The application for marketing authorization was submitted in April 2007. However, the CHMP issued a negative opinion for the drug in March 2009 because of concerns about the vaccine’s ability to trigger the production of enough antibodies against the flu virus.
“According to criteria laid down by the CHMP, a mock-up vaccine needs to bring about protective levels of antibodies in at least 70% of people for it to be considered suitable,” stated a Q&A from the EMA concerning Emerflu. “Because antibody production following Emerflu administration was below this level in the main studies (less than 40% in participants aged below 60 years), the CHMP was concerned that Emerflu was not suitable for use as a mock-up vaccine.”
Similar results were also seen in people who received the drug containing a different strain of flu virus and there were also contradictory results in the studies looking at the effects of a third dose, raising concerns about the vaccine’s low immunogenicity, regardless of the strain of virus included.
More information about the withdrawal, including the withdrawal letter from the company, will be published on the EMA website after the next CHMP meeting on 13–16 December 2010.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
